K.E. Vanover

873 total citations
24 papers, 707 citations indexed

About

K.E. Vanover is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, K.E. Vanover has authored 24 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cellular and Molecular Neuroscience, 12 papers in Molecular Biology and 3 papers in Pharmacology. Recurrent topics in K.E. Vanover's work include Receptor Mechanisms and Signaling (7 papers), Neurotransmitter Receptor Influence on Behavior (6 papers) and Neuroscience and Neuropharmacology Research (5 papers). K.E. Vanover is often cited by papers focused on Receptor Mechanisms and Signaling (7 papers), Neurotransmitter Receptor Influence on Behavior (6 papers) and Neuroscience and Neuropharmacology Research (5 papers). K.E. Vanover collaborates with scholars based in United States, Sweden and Germany. K.E. Vanover's co-authors include David M. Weiner, Jelveh Lameh, Ethan S. Burstein, Uli Hacksell, N. T. Nash, Mark R. Brann, Elizabeth Donohue, Simon C. Harvey, Tracy A. Spalding and W. L. Woolverton and has published in prestigious journals such as Biological Psychiatry, Journal of Pharmacology and Experimental Therapeutics and Pharmacology & Therapeutics.

In The Last Decade

K.E. Vanover

23 papers receiving 684 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.E. Vanover United States 10 447 309 192 87 77 24 707
Manuelle Touzard France 11 452 1.0× 320 1.0× 107 0.6× 67 0.8× 49 0.6× 14 637
Hiroshi Mitsushio Japan 12 467 1.0× 284 0.9× 125 0.7× 50 0.6× 87 1.1× 22 709
Yuko Okahisa Japan 19 280 0.6× 277 0.9× 262 1.4× 66 0.8× 76 1.0× 44 821
Geoffrey Pavey Australia 18 563 1.3× 502 1.6× 250 1.3× 36 0.4× 76 1.0× 34 922
C. Chaput France 14 689 1.5× 579 1.9× 179 0.9× 42 0.5× 51 0.7× 19 900
Torben Skarsfeldt Denmark 13 391 0.9× 240 0.8× 279 1.5× 48 0.6× 99 1.3× 26 695
Keiko Ikemoto Japan 18 504 1.1× 335 1.1× 62 0.3× 125 1.4× 81 1.1× 63 853
Lucinda J. Steward United Kingdom 17 536 1.2× 502 1.6× 65 0.3× 40 0.5× 127 1.6× 25 903
Rudi Hwang Canada 20 355 0.8× 250 0.8× 525 2.7× 54 0.6× 152 2.0× 33 1.0k
Denis Boulay France 15 587 1.3× 410 1.3× 68 0.4× 45 0.5× 83 1.1× 23 816

Countries citing papers authored by K.E. Vanover

Since Specialization
Citations

This map shows the geographic impact of K.E. Vanover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.E. Vanover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.E. Vanover more than expected).

Fields of papers citing papers by K.E. Vanover

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.E. Vanover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.E. Vanover. The network helps show where K.E. Vanover may publish in the future.

Co-authorship network of co-authors of K.E. Vanover

This figure shows the co-authorship network connecting the top 25 collaborators of K.E. Vanover. A scholar is included among the top collaborators of K.E. Vanover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.E. Vanover. K.E. Vanover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Satlin, Andrew, Suresh Durgam, K.E. Vanover, et al.. (2020). P.468 Cardiometabolic safety of lumateperone (ITI-007): post hoc analyses of short-term randomized trials and an open-label long-term study. European Neuropsychopharmacology. 40. S265–S266. 1 indexed citations
2.
Almer, Laurel S., Åsa Konradsson‐Geuken, Robert E. Davis, et al.. (2020). P.584 The actions of lumateperone and single nucleotide polymorphism (SNP) converge on the glutamate-NO-cGMP pathway. European Neuropsychopharmacology. 40. S332–S332. 1 indexed citations
3.
Correll, C.U., K.E. Vanover, Suresh Durgam, et al.. (2019). P.673 Results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia. European Neuropsychopharmacology. 29. S455–S456. 1 indexed citations
4.
Snyder, Gretchen L., Robert E. Davis, Sophie Dutheil, et al.. (2018). S81. Unique Pharmacology and Clinical Evidence Supporting the Antidepressant Therapeutic Potential of Lumateperone. Biological Psychiatry. 83(9). S378–S378. 1 indexed citations
5.
Satlin, Andrew, K.E. Vanover, Jelena Saillard, et al.. (2018). P2‐032: ITI‐007 (LUMATEPERONE) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA, INCLUDING ALZHEIMER'S DISEASE. Alzheimer s & Dementia. 14(7S_Part_12). 1 indexed citations
6.
Daniel, David G., Amir H Kalali, Mark J. West, et al.. (2016). Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders.. PubMed. 13(1-2). 27–31. 7 indexed citations
7.
8.
Tredici, Andria L. Del, K.E. Vanover, Sine Mandrup Bertozzi, et al.. (2008). Identification of novel selective V2 receptor non-peptide agonists. Biochemical Pharmacology. 76(9). 1134–1141. 5 indexed citations
9.
Vanover, K.E., Adrienne J. Betz, Stephen G. Weber, et al.. (2008). A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacology Biochemistry and Behavior. 90(4). 540–544. 65 indexed citations
10.
Lameh, Jelveh, Ethan S. Burstein, Eric B. Taylor, et al.. (2007). Pharmacology of N-desmethylclozapine☆. Pharmacology & Therapeutics. 115(2). 223–231. 81 indexed citations
11.
Piu, Fabrice, Luis R. Gardell, Thomas Son, et al.. (2007). Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. The Journal of Steroid Biochemistry and Molecular Biology. 109(1-2). 129–137. 22 indexed citations
12.
Kammen, Daniël P. van, et al.. (2006). III.P5 ACP-103 Reduces psychosis without impairing motor function in Parkinson's Disease. Parkinsonism & Related Disorders. 12. 31–31. 2 indexed citations
13.
Weiner, David M., Herbert Y. Meltzer, Isaac Veinbergs, et al.. (2004). The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology. 177(1-2). 207–216. 206 indexed citations
14.
Barrett, James E. & K.E. Vanover. (2003). Assessment of Learning and Memory Using the Autoshaping of Operant Responding in Mice. Current Protocols in Neuroscience. 25(1). Unit 8.5F–Unit 8.5F. 12 indexed citations
15.
Vanover, K.E., Simon C. Harvey, Susan B. Powell, et al.. (2003). ACP-103, A 5-HT2A receptor inverse agonist, a novel potential treatment for psychosis. Schizophrenia Research. 60(1). 317–317. 1 indexed citations
16.
Weiner, David M., Ethan S. Burstein, N. T. Nash, et al.. (2001). 5-Hydroxytryptamine2A Receptor Inverse Agonists as Antipsychotics. Journal of Pharmacology and Experimental Therapeutics. 299(1). 268–276. 169 indexed citations
17.
Vanover, K.E., et al.. (2000). Neuroactive steroids attenuate cocaine-induced sucrose intake in rats, but not cocaine-induced hyperactivity in mice. Psychopharmacology. 149(3). 269–276. 10 indexed citations
18.
Vanover, K.E., et al.. (1999). Positive allosteric modulators of the GABA A receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol. Psychopharmacology. 141(1). 77–82. 59 indexed citations
19.
Vanover, K.E. & W. L. Woolverton. (1994). Behavioral effects of the dopamine autoreceptor agonist PD 128483 alone and in combination with cocaine.. Journal of Pharmacology and Experimental Therapeutics. 270(3). 1049–1056. 7 indexed citations
20.
Vanover, K.E., Mark S. Kleven, & W. L. Woolverton. (1991). Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D1 dopamine antagonists SCH-39166 and A-66359. Behavioural Pharmacology. 2(2). 151???160–151???160. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuelle Touzard Breakdown of academic impact, for papers by Hiroshi Mitsushio Breakdown of academic impact, for papers by Yuko Okahisa Breakdown of academic impact, for papers by Geoffrey Pavey Breakdown of academic impact, for papers by C. Chaput Breakdown of academic impact, for papers by Torben Skarsfeldt Breakdown of academic impact, for papers by Keiko Ikemoto Breakdown of academic impact, for papers by Lucinda J. Steward Breakdown of academic impact, for papers by Rudi Hwang Breakdown of academic impact, for papers by Denis Boulay
Rankless by CCL
2026